TouchMDT: Precision Targeting Of MET In NSCLC: A Multidisciplinary Approach

28:30

We're trying something different this week: a full post-show breakdown of every episode in the latest season of Black Mirror! Ari Romero is joined by Tudum's Black Mirror expert, Keisha Hatchett, to give you all the nuance, the insider commentary, and the details you might have missed in this incredible new season. Plus commentary from creator & showrunner Charlie Brooker! SPOILER ALERT: We're talking about the new season in detail and revealing key plot points. If you haven't watched yet, and you don't want to know what happens, turn back now! You can watch all seven seasons of Black Mirror now in your personalized virtual theater . Follow Netflix Podcasts and read more about Black Mirror on Tudum.com .…

touchPODCAST « »
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4

大约1年之前 13:46

MP3•单集首页

touchMDT for touchONCOLOGY
Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.

The multidisciplinary team

Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK.
This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:

www.touchONCOLOGY.com

102集单集

#Science #TouchPODCAST

touchPODCAST

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4

touchPODCAST

published 大约1年之前

MP3•单集首页

touchMDT for touchONCOLOGY
Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.

The multidisciplinary team

Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

www.touchONCOLOGY.com

102集单集

#Science #TouchPODCAST

所有剧集

touchPODCAST

1
Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchNEUROLOGY 33:43

12天之前33:43

33:43

touchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of world-leading experts in lysosomal storage disorders explore treatment needs along the lifespan of people living with alpha-mannosidosis, discuss the evolving treatment landscape, and finally, reflect on how treatment advances may be integrated into the multidisciplinary management of alpha-mannosidosis, with the aim of optimizing patient outcomes. The experts Dr Barbara K. Burton, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Dr Can Ficicioglu, Children's Hospital of Philadelphia, PA, USA Dr Christina Lampe, University of Giessen, Giessen, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Chiesi USA, Inc. The activity is jointly provided by USF Health and touchIME. For further information visit: touchneurologyime.org/…

touchPODCAST

1
Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchENDOCRINOLOGY 33:45

12天之前33:45

33:45

touchPANEL DISCUSSION for touchENDOCRINOLOGY Listen to a panel of world-leading experts in lysosomal storage disorders explore treatment needs along the lifespan of people living with alpha-mannosidosis, discuss the evolving treatment landscape, and finally, reflect on how treatment advances may be integrated into the multidisciplinary management of alpha-mannosidosis, with the aim of optimizing patient outcomes. The experts Dr Barbara K. Burton, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Dr Can Ficicioglu, Children's Hospital of Philadelphia, PA, USA Dr Christina Lampe, University of Giessen, Giessen, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Chiesi USA, Inc. The activity is jointly provided by USF Health and touchIME. For further information visit: touchendocrinologyime.org/…

touchPODCAST

1
The evolving standard of care for advanced/recurrent endometrial cancer: A practice-focused discussion of immunotherapy 38:58

16天之前38:58

38:58

touchIN CONVERSATION for touchONCOLOGY Listen to two expert gynaecologic oncology specialists discuss the evolving role of immunotherapy in the treatment of advanced/recurrent endometrial cancer. They explore how immune checkpoint inhibitors are reshaping standards of care across lines of therapy, highlight key practical considerations for optimizing patient selection and management, and examine emerging data that may influence future treatment paradigms. The experts Dr Alexandra Leary, Gustave Roussy Cancer Center, Villejuif, France Dr Juan Francisco Grau, Gustave Roussy Cancer Center, Villejuif, France This touchPODCAST is for HCPs outside of the USA and UK only. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/…

touchPODCAST

1
Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia 35:35

21天之前35:35

35:35

touchPANEL DISCUSSION for touchHAEMATOLOGY Listen to three experts as they explore the burden of myelofibrosis and anaemia and/or thrombocytopenia, discuss targeted treatment strategies and how to maximize benefits for patients. The experts Prof. Haifa Kathrin Al-Ali – University Hospital of Halle, Halle (Saale), Germany Prof. Jean-Jacques Kiladjian – Université Paris Cité and Saint-Louis Hospital, Paris, France Prof. Alessandro Vannucchi – University of Florence, Florence, Italy This touchPODCAST is for HCPs outside of the UK and USA only. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/…

touchPODCAST

1
Video 3: MDT perspectives on identifying and managing key ADC treatment toxicities in patients with metastatic breast cancer 11:54

23天之前11:54

11:54

Listen to key experts from a multidisciplinary team consider the strategies to avoid, mitigate, identify and effectively manage side effects associated with ADCs in patients with metastatic breast cancer. The multidisciplinary team Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA Clinical oncology pharmacy specialist: Dr Scott Edwards, Dr. H. Bliss Murphy Cancer Center, St. John’s, Newfoundland, Canada This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com…

touchPODCAST

1
Video 2: MDT perspectives on communicating ADC treatment toxicities to patients with metastatic breast cancer 13:03

23天之前13:03

13:03

Listen to key experts from a multidisciplinary team discuss effective strategies for communicating the potential side effects associated with ADC treatment to patients with metastatic breast cancer. The multidisciplinary team Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA Patient advocate: Mrs Lesley Turner, Independent Cancer Patients’ Voice, UK This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com…

touchPODCAST

1
Video 1: MDT perspectives on the safety profiles of current and emerging ADCs in metastatic breast cancer 11:59

23天之前11:59

11:59

Listen to key experts from a multidisciplinary team review and discuss the safety profiles of current and emerging ADCs in patients with metastatic breast cancer. The multidisciplinary team Medical oncologist: Dr Véronique Diéras, Centre Eugène Marquis, Rennes, France Nurse practitioner: Dr Kayla Freeman, Emory Winship Cancer Institute, Atlanta, GA, USA This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com…

touchPODCAST

1
Precision in practice: Adopting emerging therapies for retinal diseases to reduce burden of disease 19:12

23天之前19:12

19:12

touchEXPERT FOCUS for touchOPHTHALMOLOGY Listen to retina specialist Prof. Peter Kaiser answer a series of questions on the current clinical landscape for neovascular age-related macular degeneration and diabetic macular oedema, share his perspective on how newly available treatments are influencing the existing standard of care and provide guidance on how new therapies can be effectively integrated into clinical practice. The expert Prof. Peter Kaiser, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA This touchPODCAST is for HCPs outside of the USA and UK only. This activity is funded by an independent medical education grant from Bayer Consumer Care AG. The activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchophthalmologyime.org/adopting-emerging-therapies-for-retinal-diseases…

touchPODCAST

1
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice 1:06:26

5 weeks之前1:06:26

1:06:26

touchCONGRESS for touchCARDIO Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice. Overview Data reviews with Prof. Mozaffar, Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below Clinical themes Clinical and real-world data on long-term outcomes in Pompe disease Outcomes and impact of treatment switching in Pompe disease Latest clinical data on current and emerging therapies in Pompe disease The internationally renowned Pompe disease expert faculty Prof. Tahseen Mozaffar, Irvine, CA, USA Dr Jennifer L Cohen, Durham, NC, USA Prof. Benedikt Schoser, Munich, German This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:…

touchPODCAST

1
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice 1:06:27

5 weeks之前1:06:27

1:06:27

touchCONGRESS for touchENDOCRINOLOGY Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice. Overview Data reviews with Prof. Mozaffar, Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below Clinical themes Clinical and real-world data on long-term outcomes in Pompe disease Outcomes and impact of treatment switching in Pompe disease Latest clinical data on current and emerging therapies in Pompe disease The internationally renowned Pompe disease expert faculty Prof. Tahseen Mozaffar, Irvine, CA, USA Dr Jennifer L Cohen, Durham, NC, USA Prof. Benedikt Schoser, Munich, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:…

touchPODCAST

1
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice 1:06:26

5 weeks之前1:06:26

1:06:26

touchCONGRESS for touchNEUROLOGY Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice. Overview Data reviews with Prof. Mozaffar, Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below Clinical themes Clinical and real-world data on long-term outcomes in Pompe disease Outcomes and impact of treatment switching in Pompe disease Latest clinical data on current and emerging therapies in Pompe disease The internationally renowned Pompe disease expert faculty Prof. Tahseen Mozaffar, Irvine, CA, USA Dr Jennifer L Cohen, Durham, NC, USA Prof. Benedikt Schoser, Munich, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:…

touchPODCAST

1
Expanding horizons for patients with Pompe disease Using data to guide clinical practice 1:06:27

5 weeks之前1:06:27

1:06:27

touchCONGRESS for touchRESPIRATORY Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice. Overview Data reviews with Prof. Mozaffar, Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below Clinical themes Clinical and real-world data on long-term outcomes in Pompe disease Outcomes and impact of treatment switching in Pompe disease Latest clinical data on current and emerging therapies in Pompe disease The internationally renowned Pompe disease expert faculty Prof. Tahseen Mozaffar, Irvine, CA, USA Dr Jennifer L Cohen, Durham, NC, USA Prof. Benedikt Schoser, Munich, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Amicus Therapeutics. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:…

touchPODCAST

1
MDT perspectives on the importance of patient engagement in PARPi use - Video 3 13:21

7 weeks之前13:21

13:21

touchMDT for touchONCOLOGY Listen to experts Dr Alicia Morgans, Dr Grace Cullen, and patient advocate, Mr Tony Collier, discuss the importance and practicalities of engaging patients in their care and hear insights from the perspective of a patient advocate in relation to the use of PARP inhibitors. The multidisciplinary team and patient advocate: Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA Patient Advocate – Mr Tony Collier Tackle Prostate Cancer, London, UK This touchPODCAST is for HCPs outside of the UK only. This activity is supported by an independent medical education funding request from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/…

touchPODCAST

1
MDT perspectives on understanding precision medicine to guide PARPi use in mCRPC - Video 2 13:45

7 weeks之前13:45

13:45

touchMDT for touchONCOLOGY Somatic and germline testing are key in managing metastatic castration-resistant prostate cancer (mCRPC). Listen as Prof. Albrecht Stenzinger shares his perspectives as a pathologist with Dr Alicia Morgan and Dr Grace Cullen. The multidisciplinary team: Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA Pathologist – Prof. Albrecht Stenzinger University of Heidelberg, Heidelberg, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is supported by an independent medical education funding request from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/…

touchPODCAST

1
MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC - Video 1 13:44

7 weeks之前13:44

13:44

touchMDT for touchONCOLOGY MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC Experts Dr Alicia Morgans and Dr Grace Cullen share insights into using evidence to guide practice and shared decision-making with patients with metastatic castration-resistant prostate cancer (mCRPC). The multidisciplinary team: Medical oncologist – Dr Alicia Morgans Dana-Farber Cancer Institute, Boston, Massachusetts, USA Nurse practitioner – Dr Grace Cullen John D. Dingell VA Medical Center, Detroit, Michigan, USA This touchPODCAST is for HCPs outside of the UK only. This activity is supported by an independent medical education funding request from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/…

touchPODCAST

1
The next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGY 32:02

8 weeks之前32:02

32:02

touchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D). The experts Dr Sue Pedersen, University of Calgary, Calgary, Canada Prof. Carel le Roux, University College Dublin, Dublin, Ireland Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA This touchPODCAST is for healthcare professionals outside of the USA and UK. This activity is funded by an independent medical education grant from Novo Nordisk A/S. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchENDOCRINOLOGY.com…

touchPODCAST

1
The next frontier in managing obesity and T2D: The role of novel combinations for touchCARDIO 32:01

8 weeks之前32:01

32:01

touchEXPERT OPINIONS for touchCARDIO Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D). The experts Dr Sue Pedersen, University of Calgary, Calgary, Canada Prof. Carel le Roux, University College Dublin, Dublin, Ireland Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA This touchPODCAST is for healthcare professionals outside of the USA and UK. This activity is funded by an independent medical education grant from Novo Nordisk A/S. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchCARDIO.com…

touchPODCAST

1
From clinical trials to clinical practice: Applying CDK4/6 inhibitors in HR+/HER2– early breast cancer 36:50

9 weeks之前36:50

36:50

touchEXPERT OPINIONS for touchONCOLOGY Listen to three experts in breast cancer as they provide insights into the current guideline recommendations for the use of targeted therapy in patients with HR+/HER2– early breast cancer, evaluate the latest data for CDK4/6 inhibitors in this patient population and consider how to maximize the potential of these agents through risk stratification and safety considerations. The experts Prof. Carlos Barrios: Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil Prof. Dr. med. Peter Fasching: University Hospital Erlangen and Comprehensive Cancer Center, Erlangen-EMN, Germany Dr Sonia Pernas: Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain This touchPODCAST is for healthcare professionals outside of the UK and the USA. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. For further information visit our website: www.touchONCOLOGY.com…

touchPODCAST

1
Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals 36:26

9 weeks之前36:26

36:26

touchIN CONVERSATION for touchINFECTIOUS DISEASES Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings. The experts Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA Dr Marc Steben, HPV Global Action and Université de Montréal, Canada This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC ® accredited provider. For further information visit our website: https://touchinfectiousdiseasesime.org/in-conversation-improving-hpv-vaccine-uptake/…

touchPODCAST

1
Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals 36:26

9 weeks之前36:26

36:26

touchIN CONVERSATION for touchONCOLOGY Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings. The experts Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA Dr Marc Steben, HPV Global Action and Université de Montréal, Canada This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC ® accredited provider. For further information visit our website: https://touchoncologyime.org/in-conversation-improving-hpv-vaccine-uptake/…

touchPODCAST

1
Looking to the future in the treatment of steroid-refractory chronic GvHD 16:31

9 weeks之前16:31

16:31

touchFOCUS for touchHAEMATOLOGY In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies. The expert: Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from Sanofi US. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchHAEMATOLOGY.com…

touchPODCAST

1
Looking to the future in the treatment of steroid-refractory chronic GvHD 16:31

9 weeks之前16:31

16:31

touchFOCUS for touchONCOLOGY In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies. The expert: Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from Sanofi US. This activity is jointly provided by USF Health and touchIME. For further information visit our website: touchoncology.com…

touchPODCAST

1
Updates in BCMA-directed therapies in multiple myeloma from ASH 2024 55:57

11 weeks之前55:57

55:57

touchCONGRESS for ONCOLOGY Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. The experts Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic This touchPODCAST is for HCPs outside of the USA and UK. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/…

touchPODCAST

1
Updates in BCMA-directed therapies in multiple myeloma from ASH 2024 55:57

11 weeks之前55:57

55:57

touchCONGRESS for touchHAEMATOLOGY Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. The experts Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic This touchPODCAST is for HCPs outside of the USA and UK. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/…

touchPODCAST

1
RAS mutations and personalized cancer care: Targeting the future 31:02

12 weeks之前31:02

31:02

touchEXPERT OPINIONS for touchONCOLOGY Listen to a medical oncologist, a pancreatic cancer specialist and a lung cancer specialist discuss the role of RAS mutations in solid tumours, notably pancreatic cancer and NSCLC, and how they may be therapeutically targeted to improve patient outcomes. The experts Dr David S Hong, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Dr Eileen M O’Reilly, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA Dr Rebecca S Heist, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA This touchPODCAST is for healthcare professionals outside of the UK. This activity is funded by an independent medical education grant from Revolution Medicines . This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/mutations-and-personalized-cancer-care-targeting-the-future/…

touchPODCAST

1
What’s new in primary ITP? Key updates from ASH 2024 40:35

12 weeks之前40:35

40:35

touchPANEL DISCUSSION for touchONCOLOGY Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition. The experts Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#…

touchPODCAST

1
What’s new in primary ITP? Key updates from ASH 2024 40:35

12 weeks之前40:35

40:35

touchPANEL DISCUSSION for touchHAEMATOLOGY Listen to three expert haematologists as they explore how immune thrombocytopenia (ITP) is managed today, emerging targeted treatments and the real-world impact of ITP. The faculty share their insights and review the latest data on these topics from the 66th American Society of Hematology Annual Meeting & Exposition. The experts Dr Hanny Al-Samkari – Massachusetts General Hospital, Boston, MA, USA Dr Drew Provan – Barts and The London School of Medicine and Dentistry, London, UK Dr Barbara Skopec – University Medical Centre Ljubljana, Ljubljana, Slovenia This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. TouchIME is an EBAC® accredited provider. For further information visit our website: https://touchhaematologyime.org/itp-key-updates-from-ash-2024/#…

touchPODCAST

1
Focused insights: Data implications of ADCs in NSCLC treatment 21:54

13 weeks之前21:54

21:54

touchFOCUS for touchRESPIRATORY Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future. The expert Prof. Céline Mascaux, Strasbourg University, Strasbourg, France This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchrespiratory.org/ADCs-in-NSCLC…

touchPODCAST

1
Focused insights: Data implications of ADCs in NSCLC treatment 21:54

13 weeks之前21:54

21:54

touchFOCUS for touchONCOLOGY Listen to Prof. Céline Mascaux, an expert in thoracic oncology, answer a series of questions on the latest efficacy and safety data for ADCs in the treatment of patients with NSCLC in the first- and second-line setting, and place these data in the context of current standards of care. She also considers how these data may impact clinical practice in the future. The expert Prof. Céline Mascaux, Strasbourg University, Strasbourg, France This touchPODCAST is for HCPs only This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchoncology.org/ADCs-in-NSCLC…

touchPODCAST

1
Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchONCOLOGY 1:20:58

13 weeks之前1:20:58